The Manufacturers Life Insurance Company Has $1.44 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

The Manufacturers Life Insurance Company increased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 3.7% in the 2nd quarter, HoldingsChannel reports. The firm owned 80,664 shares of the biopharmaceutical company’s stock after acquiring an additional 2,871 shares during the period. The Manufacturers Life Insurance Company’s holdings in TG Therapeutics were worth $1,435,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in TGTX. Eventide Asset Management LLC acquired a new stake in TG Therapeutics during the fourth quarter worth approximately $7,506,000. Wellington Management Group LLP boosted its holdings in TG Therapeutics by 1.4% in the fourth quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company’s stock worth $53,627,000 after acquiring an additional 43,290 shares in the last quarter. Vanguard Group Inc. boosted its holdings in TG Therapeutics by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 13,670,944 shares of the biopharmaceutical company’s stock worth $233,500,000 after acquiring an additional 199,770 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in TG Therapeutics by 55.8% in the first quarter. Los Angeles Capital Management LLC now owns 76,616 shares of the biopharmaceutical company’s stock worth $1,165,000 after acquiring an additional 27,437 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in TG Therapeutics by 16.9% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 184,815 shares of the biopharmaceutical company’s stock worth $2,811,000 after acquiring an additional 26,761 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on TGTX shares. HC Wainwright reiterated a “buy” rating and issued a $49.00 price target on shares of TG Therapeutics in a report on Wednesday, September 18th. B. Riley raised their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group raised their target price on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.83.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $22.18 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The business has a fifty day simple moving average of $22.76 and a two-hundred day simple moving average of $19.02. TG Therapeutics, Inc. has a 1 year low of $6.46 and a 1 year high of $26.41. The company has a market capitalization of $3.43 billion, a P/E ratio of 36.36 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.08. The company had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The firm’s quarterly revenue was up 357.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.34) earnings per share. On average, analysts expect that TG Therapeutics, Inc. will post 0.13 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.